Tirzepatide vs. Insulin Glargine: A Phase 3 Study for Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk
Background
Type 2 Diabetes Mellitus is a chronic metabolic disorder characterized by high blood sugar, often leading to serious complications, including increased cardiovascular risk. Current treatments aim to control blood glucose, but many patients still struggle to achieve optimal glycemic control and manage associated risks. This Phase 3 study, SURPASS-4, was designed to directly compare the efficacy and safety of once-weekly tirzepatide against once-daily insulin glargine in patients with type 2 diabetes and elevated cardiovascular risk.
Study Design
Population
Patients with type 2 diabetes and elevated cardiovascular risk were studied in this Phase 3 trial.
Intervention
Once-weekly tirzepatide was administered.
Comparator
Once-daily insulin glargine was used as an active comparator.
Outcome
The study directly compared the efficacy and safety of tirzepatide against insulin glargine.